Skip to main content
. 2020 Sep 18;12(9):2659. doi: 10.3390/cancers12092659

Figure 7.

Figure 7

cam1615B7H3 TriKE is efficacious in subduing ovarian tumor progression in vivo. (A) Diagram showing Xenogeneic ovarian cancer MA-148-Luc model in female NSG mice (N = 5 per treatment group). (B) Bioluminescent imaging indicative of tumor progression, measured as Total flux radiance (p/s), over three weeks in the MA148 mouse model treated with enriched NK cells and noted treatments. (C) Bioluminescent imaging results on day 21 data point. (D) Graphed total flux radiance (p/s) on day 21. (E) Scatter plot of CD56+CD3− NK cell numbers from peritoneal lavages for the rhIL-15 and cam1615B7H3 TriKE treatment groups at D21. (F) Scatter plot of CD16 media fluorescence intensity on NK cells from peritoneal lavages for the rhIL-15 and cam1615B7H3 TriKE treatment groups at day 21. * p < 0.05, ** p < 0.01.